Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer

Clinical Trial Results:
Ifinatamab deruxtecan, a B7-H3 directed DXd antibody-drug conjugate (ADC), has shown promising objective response rates in patients with extensive-stage small cell lung cancer (SCLC) in the IDEATE-Lung01 Phase 2 trial.

Collaboration:
Daiichi Sankyo and Merck have a global collaboration to jointly develop and commercialize ifinatamab deruxtecan, along with other ADCs including patritumab deruxtecan and raludotatug deruxtecan, except in Japan where Daiichi Sankyo maintains exclusive rights.

Phase 3 Trial Initiation:
The IDeate-Lung02 Phase 3 trial has been initiated to evaluate the efficacy and safety of ifinatamab deruxtecan in patients with relapsed SCLC versus treatment of physician’s choice of chemotherapy.

ADC Technology:
Daiichi Sankyo’s proprietary DXd ADC technology is used to target and deliver a cytotoxic payload inside cancer cells that express a specific cell surface antigen, such as B7-H3 in SCLC.

Disease Background:
Small cell lung cancer is aggressive and has a poor prognosis, with a five-year survival rate of only 3% for metastatic stage patients, and approximately 65% of SCLC tumors have moderate-to-high expression of B7-H3.

Research Presentations:
Daiichi Sankyo will present new clinical research across its ADC portfolio, including data on ifinatamab deruxtecan, at the IASLC 2024 World Conference on Lung Cancer and the 2024 European Society for Medical Oncology.